NCT00192166已完成2 期
Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 1,200
- 试验地点
- 2
- 主要终点
- All episodes of AOM, occurring during the influenza season, associated with a positive culture for influenza virus antigenically similar to those contained in the vaccine.
研究概览
简要总结
- The primary objective of the study was to determine if intranasally administered influenza virus vaccine, CAIV-T), when administered concomitantly with a subcutaneously administered combination live, attenuated mumps, measles, and rubella (MMR) virus vaccine to children interferes with the immune responses.
详细描述
- The primary objective of the study was to determine if intranasally administered influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T), when administered concomitantly with a subcutaneously administered combination live, attenuated mumps, measles, and rubella (MMR) virus vaccine to children aged 11 to less than 24 months, interferes with the immune responses to the measles, mumps, and rubella components of the MMR vaccine.
- To compare the efficacy over one season against culture-confirmed influenza-illness caused by community-acquired subtypes antigenically similar to those contained in the vaccine, in children who are aged at least 11 months and less than 24 months at enrollment, between those who receive two doses of CAIV-T and those who receive placebo, each with concomitant administration of a combination live, attenuated MMR vaccine administered prior to the anticipated commencement of the influenza season.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- Double
入排标准
- 年龄范围
- 11 Months 至 24 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •who were at least 11 months of age and less than 24 months of age at the time of first vaccination
- •who were due to receive their first dose of combined measles, mumps, and rubella vaccine (MMR)
- •who were in good health as determined by medical history, physical examination and clinical judgment
- •whose parent(s)/legal guardian(s) provided written informed consent after the nature of the study was explained
- •who, along with their parent(s)/legal guardian(s), were available for duration of the trial (approximately 8 months)
- •whose parent(s)/legal guardian(s), could be reached by study staff for the post-vaccination contact (telephone, clinic or home visit)
排除标准
- •whose parent(s)/legal guardian(s) were perceived to be unavailable or difficult to contact for evaluation or study visits during the study period
- •who had any serious chronic disease (eg, with signs of cardiac or renal failure or severe malnutrition), including progressive neurological disease
- •who had Down's syndrome or other known cytogenetic disorders who had a known or suspected disease of the immune system or those who received immunosuppressive therapy, including systemic corticosteroids. Subjects receiving high doses of systemic corticosteroids given daily or on alternate days, for 14 days or more, were excluded from vaccination until corticosteroid therapy was discontinued for at least one month. High doses were defined as 2 mg/kg/day or more of prednisolone or its equivalent, or 20 mg/day or more for children who weighed more than 10 kg.38
- •who received, or were anticipated to receive, any blood products, including immunoglobulin, in the period from 6 months prior to vaccination through to the conclusion of the study
- •for whom there was intent to administer any other investigational vaccine or agent from one month prior to enrollment through to the conclusion of the study had an immunosuppressed or an immunocompromised individual living in the same household
- •who, at any time prior to entry into this study, received a dose of any influenza vaccine (commercial or investigational)
- •who, at any time prior to entry into this study, received a dose of MMR vaccine or any of the individual components of the MMR vaccine (commercial or investigational)
- •who were anticipated to receive a subsequent dose of MMR within 1 month after receipt of the second dose of CAIV-T or placebo
- •with a documented history of hypersensitivity to egg or egg protein or any other components of CAIV-T or MMR
- •who received aspirin (acetylsalicylic acid) or aspirin-containing products in the 2 weeks prior to vaccination or for which use is anticipated during the study
- •with any medical conditions that in the opinion of the Investigator might have interfered with interpretation of the study results
- •Note: Pregnancy in any person who had regular contact with the subject was not a contraindication to the enrollment or ongoing participation of the subject in the study.
结局指标
主要结局
All episodes of AOM, occurring during the influenza season, associated with a positive culture for influenza virus antigenically similar to those contained in the vaccine.
次要结局
- The first episode during the influenza season of AOM associated with a positive culture for influenza virus; all episodes during the influenza season of AOM; all during the influenza season, of AOM associated with fever.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Efficacy Safety Study of Flu Vaccine in Immunodepression PatientsInflammatory Bowel Disease (IBD)NCT01022749Assistance Publique - Hôpitaux de Paris228
已完成
4 期
Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle SyringeInfluenza ProphylaxisNCT01644149PharmaJet, Inc.83
已完成
不适用
Antibody Response to Influenza Vaccine in Patients With SarcoidosisPulmonary SarcoidosisNCT00828828Shahid Beheshti University of Medical Sciences49
已完成
3 期
Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM VaccineInfluenzaNCT00554333Sanofi Pasteur, a Sanofi Company795
已完成
3 期
The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)InfluenzaNCT01551810Institute of Medical Biology, Chinese Academy of Medical Sciences1,200